Search

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

… Tuesday, October 14, 2014 Summary Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer. Genetic inheritance is most commonly thought of as the passing of genes from parent to child

Learn how cancer patients benefit from carefully considered design at Memorial Sloan Kettering, from the director of its design team.

… Wednesday, November 20, 2019 People in a waiting room The transfusion areas at MSK facilities, including those at The David H. Koch Center for Cancer Care at Memorial Sloan Kettering, give people easy access to care teams and provide a choice between privacy or socializing with other patients and caregivers

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing.

… Tuesday, July 28, 2020 Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since U.S. News & World Report established the prestigious rankings more than 30 years ago

During the AACR COVID-19 and Cancer Meeting, several MSK physicians presented information about providing safe patient care, vaccines, and clinical research.

… Friday, February 12, 2021 At the American Association for Cancer Research (AACR) COVID-19 and Cancer Meeting on February 3-5, 2021, oncology experts from around the world tuned in virtually to discuss the impact of COVID-19 on cancer care. The meeting featured presentations of emerging data in basic,

In February, Harold Varmus' memoir about his life in science was published.

… Sunday, March 1, 2009 Summary In February, Harold Varmus’ memoir about his life in science was published. The Art and Politics of Science, Harold Varmus In February, W. W. Norton & Company published Memorial Sloan Kettering Cancer Center President Harold Varmus’ memoir about his life in science. The

GSK's Third Biennial Retreat, April 25-26, will feature clinician-scientist Todd R. Golub in Skytop, Pennsylvania.

… Tuesday, April 22, 2014 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences’ (GSK) Third Biennial Retreat will take place from April 25–26 at Skytop Lodge in Skytop, Pennsylvania. The retreat will feature clinician-scientist Todd R. Golub as the keynote speaker. A founding director and

Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.

… Thursday, September 6, 2012 Summary Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms. Memorial Sloan Kettering researchers have discovered why a class of drugs called JAK2 inhibitors has not been

… Tuesday, September 3, 2024 Dear MSK Community, Our knowledge of cancer — what it is and how it progresses — has developed at a staggering pace over the past 20 years. Today, thanks to remarkable advances in the understanding of how cancer cells behave and evolve, many led by MSK, researchers have devised

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Wednesday, April 27, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Jorge S. Reis-Filho Named a Susan G. Komen Scholar Jorge S. Reis-Filho Jorge S. Reis-Filho, MD, PhD, FRCPath, Chief, Experimental Pathology Service, was named a Susan G. Komen Scholar

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.

… Thursday, January 9, 2025 Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic